Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai

You may also be interested in...



Asia Spotlight: WuXi AppTec Senior VP Richard Soll On China’s Pharma Evolution

Soll talks about the transition of China’s top CRO from a preclinical play to an integrated services provider for innovative drug development.

WuXi AppTec SVP Richard Soll On China’s Pharma Evolution: An Interview With PharmAsia News

Soll talks about the transition of China’s top CRO from a preclinical play to an integrated services provider for innovative drug development.

WuXi Forms JV With PRA To Expand Clinical Services In China

WuXi PharmaTech forms a joint venture with U.S. contract research organization PRA to grow its clinical capabilities in China; the move expands PRA’s reach to 16 Chinese cities.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel